EBS Emergent BioSolutions Inc

Price (delayed)

$98.80

Market cap

$5.27B

P/E Ratio

17.06

Dividend/share

N/A

EPS

$5.79

Enterprise value

$5.52B

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Highlights

The net income has soared by 83% from the previous quarter
EBS's EPS has soared by 82% since the previous quarter
Emergent BioSolutions's debt has increased by 8% YoY

Key stats

What are the main financial stats of EBS
Market
Shares outstanding
53.3M
Market cap
$5.27B
Enterprise value
$5.52B
Valuations
Price to earnings (P/E)
17.06
Price to book (P/B)
3.62
Price to sales (P/S)
3.35
EV/EBIT
12.59
EV/EBITDA
9.98
EV/Sales
3.55
Earnings
Revenue
$1.56B
EBIT
$438.5M
EBITDA
$553M
Free cash flow
$395M
Per share
EPS
$5.79
Free cash flow per share
$7.5
Book value per share
$27.3
Revenue per share
$29.51
TBVPS
$37.07
Balance sheet
Total assets
$2.88B
Total liabilities
$1.44B
Debt
$874.8M
Equity
$1.45B
Working capital
$811.4M
Liquidity
Debt to equity
0.6
Current ratio
3.11
Quick ratio
2.22
Net debt/EBITDA
0.46
Margins
EBITDA margin
35.6%
Gross margin
66.3%
Net margin
19.6%
Operating margin
27.9%
Efficiency
Return on assets
11.9%
Return on equity
24.5%
Return on invested capital
24.7%
Return on capital employed
17.5%
Return on sales
28.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

EBS stock price

How has the Emergent BioSolutions stock price performed over time
Intraday
5.68%
1 week
-19.35%
1 month
-7.77%
1 year
60.81%
YTD
10.27%
QTD
10.27%

Financial performance

How have Emergent BioSolutions's revenue and profit performed over time
Revenue
$1.56B
Gross profit
$1.03B
Operating income
$433.8M
Net income
$305.1M
Gross margin
66.3%
Net margin
19.6%
The company's operating margin has surged by 171% YoY and by 47% QoQ
The net income has soared by 83% from the previous quarter
EBS's operating income has soared by 71% from the previous quarter
Emergent BioSolutions's net margin has surged by 57% QoQ

Growth

What is Emergent BioSolutions's growth rate over time

Valuation

What is Emergent BioSolutions stock price valuation
P/E
17.06
P/B
3.62
P/S
3.35
EV/EBIT
12.59
EV/EBITDA
9.98
EV/Sales
3.55
EBS's EPS has soared by 82% since the previous quarter
The P/E is 74% lower than the 5-year quarterly average of 66.9 and 41% lower than the last 4 quarters average of 28.9
The price to book (P/B) is 34% higher than the 5-year quarterly average of 2.7 and 3.4% higher than the last 4 quarters average of 3.5
EBS's equity is up by 33% year-on-year and by 16% since the previous quarter
The company's revenue rose by 41% YoY and by 17% QoQ
The P/S is 8% above the 5-year quarterly average of 3.1

Efficiency

How efficient is Emergent BioSolutions business performance
EBS's ROS has soared by 169% year-on-year and by 46% since the previous quarter
The company's return on assets has surged by 72% QoQ
EBS's return on equity has surged by 70% since the previous quarter
EBS's ROIC has soared by 69% QoQ

Dividends

What is EBS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for EBS.

Financial health

How did Emergent BioSolutions financials performed over time
The total assets is 101% more than the total liabilities
The total assets has grown by 24% YoY and by 10% from the previous quarter
The company's total liabilities rose by 16% YoY and by 5% QoQ
Emergent BioSolutions's debt is 40% lower than its equity
EBS's equity is up by 33% year-on-year and by 16% since the previous quarter
The debt to equity has decreased by 20% YoY and by 14% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.